人工智能与癌症药物研发。
Artificial Intelligence and Cancer Drug Development.
机构信息
Healthville Primary Care, Little Rock, AR 72211, USA.
Department of Chemistry, University of Arkansas at Little Rock, AR 72204, USA.
出版信息
Recent Pat Anticancer Drug Discov. 2022;17(1):2-8. doi: 10.2174/1574892816666210728123758.
BACKGROUND
The development of cancer drugs is among the most focused "bench to bedside activities" to improve human health. Because of the amount of data publicly available to cancer research, drug development for cancers has significantly benefited from big data and Artificial Intelligence (AI). In the meantime, challenges, like curating the data of low quality, remain to be resolved.
OBJECTIVES
This review focused on the recent advancements and challenges of AI in developing cancer drugs.
METHODS
We discussed target validation, drug repositioning, design, and compounds' synthetic strategies.
RESULTS AND CONCLUSION
AI can be applied to all stages during drug development, and some excellent reviews detailing the applications of AI in specific stages are available.
背景
开发癌症药物是提高人类健康最受关注的“从实验室到病床”的活动之一。由于癌症研究的公开数据量巨大，大数据和人工智能（AI）极大地促进了癌症药物的开发。与此同时，仍存在一些挑战，例如整理低质量的数据。
目的
本文综述了人工智能在开发癌症药物方面的最新进展和挑战。
方法
我们讨论了靶标验证、药物重定位、设计和化合物的合成策略。
结果和结论
人工智能可应用于药物开发的所有阶段，并且有一些详细介绍人工智能在特定阶段应用的优秀综述。
Zotero 插件